Effect of Thymus Pentapeptide Combined with Routine Antituberculosis Regimen on Immune Response and Lung Function in Patients with Pulmonary Tuberculosis

Abstract

Abstract: Objective To analyze the effect of thymus pentapeptide combined with conventional antituberculosis regimen in patients with pulmonary tuberculosis. Methods The medical records of 80 tuberculosis patients diagnosed and treated by Rizhao Tuberculosis Prevention and Control Institute from April 2021 to April 2022 were retrospectively analyzed and divided into two groups according to different treatment methods. Among them, 40 patients treated with conventional anti-tuberculosis regimen (2HRZE/4HR) were included in the control group, and 40 patients treated with thymus pentapeptide combined with conventional anti-tuberculosis regimen were included in the observation group. Sputum negative conversion rate, focus absorption rate, immune function, lung function and adverse reactions were compared between the two groups. Results After 2 months and 8 months of treatment, the sputum negative conversion rate and obvious focus absorption rate in the observation group were higher than those in the control group, with statistical differences (P<0.05). Before treatment, CD3⁺, CD4⁺ and CD8⁺ had no statistical differences in forced vital capacity (FVC), forced breathing volume at the first second (FEV₁) and peak expiratory flow (PEF) between the two groups (P>0.05). After treatment, CD3⁺, CD4⁺, FVC, FEV₁ and PEF in the observation group were higher than those in the control group, while CD8⁺ was lower than those in the control group, with statistical difference (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Thymus pentapeptide and conventional anti-tuberculosis regimen has an obvious effect in patients with pulmonary tuberculosis, which can accelerate sputum negative conversion, promote lesion absorption, and significantly improve immune function and lung function without serious adverse reactions. Therefore, it has high clinical application value and is worthy of vigorous implementation.

Key words: tuberculosis, thymus pentapeptide, antituberculosis therapy, immune function

CLC Number:

R521

JI Tong-zhen. Effect of Thymus Pentapeptide Combined with Routine Antituberculosis Regimen on Immune Response and Lung Function in Patients with Pulmonary Tuberculosis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(16): 15-18.

References

[1] 赵敏,黄世明,杨国华,等.2HREZS/6HRE化疗方案对复治肺结核的疗效研究[J].重庆医学,2020,49(2):244-247.
[2] 李学刚,王隽.注射用重组人白细胞介素-2辅助治疗初治涂阳肺结核患者免疫水平和不良反应的临床分析[J].中国临床医生杂志,2020,48(12):1427-1429.
[3] 袁平,杨铭,吴桂辉,等.贝达喹啉治疗耐多药、广泛耐药肺结核患者的疗效和安全性观察[J].四川医学,2022,43(6):588-592.
[4] 方刚,顾小燕,尹小芳.母牛分枝杆菌菌苗辅助抗结核方案治疗肺结核对患者免疫功能及疾病转归的影响[J].中国临床研究,2020,33(4):501-504.
[5] 杜光明,熊暁琪,杨忠诚.注射用重组人白细胞介素-2联合2HRZE/4HR方案对肺结核患者病灶吸收率和免疫功能的影响[J].临床和实验医学杂志,2022,21(8):811-814.
[6] 李福利,刘捷凌,冷霞,等.胸腺五肽辅助左氧氟沙星治疗对复治菌阳肺结核患者呼吸功能、免疫功能及炎性因子的影响[J].四川生理科学杂志,2021,43(6):1003-1004,1007.
[7] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.肺结核基层诊疗指南(2018年)[J].中华全科医师杂志,2019,18(8):709-717.
[8] 任欣欣,冯秀莉,崔丹,等.利奈唑胺联合环丝氨酸胶囊治疗肺结核对患者免疫细胞以及X-pert MTB/RIF以及肺CT的影响研究[J].中国CT和MRI杂志,2022,20(1):63-66.
[9] 李华,许婉华,龚兰,等.血清中相关细胞因子表达水平变化对肺结核治疗效果的评估[J].实用医学杂志,2022,38(17):2203-2208.
[10] 刘晓华,林瑞,杨瑶,等.利奈唑胺联合环丝氨酸治疗对耐多药肺结核T淋巴细胞亚群、痰菌转阴率及干扰素-γ的影响[J].解放军医药杂志,2022,34(5):55-57.
[11] 黄艳,张向荣,刘裔.结核丸联合肺结核标准化疗方案治疗肺结核的临床疗效及对IgG、IgA、IgM水平的影响研究[J].中华中医药学刊,2022,40(4):255-258.
[12] 周亚飞. 康复新辅助胸腺五肽治疗复治菌阳肺结核的效果[J].国际流行病学传染病学杂志,2020,47(2):107-110.
[13] 孟素华. 莫西沙星联合胸腺五肽对肺结核患者痰上清液细胞因子水平的影响[J].河北医药,2020,42(6):900-902,906.
[14] 刁利霞,吴宇平,邓俊亮.胸腺五肽联合常规抗结核化疗方案在复治涂阳肺结核治疗中的应用[J].海南医学,2021,32(7):892-894.
[15] 赵兴忠,赵新国,朱峰.康复新液联合胸腺五肽治疗肺结核患者的效果及对免疫功能的影响[J].徐州医科大学学报,2020,40(7):505-508.